Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals via Honasa Health
Mamaearth parent Honasa Consumer is acquiring a 58% stake in nutraceuticals firm Fluence Pharma at a ₹135 crore enterprise value, with the remaining 42% to be picked up over 5-7 years. The deal launches a new subsidiary, Honasa Health, marking the BPC major's formal entry into India's ₹16,000-crore nutraceuticals category.
What happened
Honasa Consumer (Mamaearth parent) is acquiring 58% of nutraceuticals firm Fluence Pharma at ₹135 crore EV, with the remaining 42% over 5-7 years. It marks
Key facts
- 58% stake
- ₹135 crore enterprise value
- 42% remaining stake
- 5-7 years
- ₹16,000 crore market
Why this matters
Staggered majority-then-full acquisitions are the playbook for adjacent-category entry in India — watch for similar BPC-to-wellness moves from Nykaa, Marico, and Dabur.